Literature DB >> 24310810

The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.

Akira Iwaku1, Akiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Hirokazu Nishino, Masato Matsushima, Hisao Tajiri.   

Abstract

The Glasgow Prognostic Score (GPS) and neutrophil to lymphocyte ratio (NLR) are associated with the survival in patients with various types of malignancy. The aim of this study was to investigate the prognostic value of the GPS and NLR in patients with biliary tract cancer (BTC) undergoing palliative chemotherapy or best supportive care (BSC). Fifty-two patients with newly diagnosed BTC were retrospectively evaluated. We investigated the correlation between the GPS, NLR, and the overall survival rates. The area under the receiver operating characteristics curve (AUC) was calculated to compare the predictive ability of each score. Both the univariate and multivariate analyses were performed to identify clinicopathological variables associated with the overall survival. There were significant differences between the GPS groups regarding the neutrophil levels (p < 0.0001), Hb (p = 0.024), Alb (p < 0.0001) and CRP (p < 0.0001). A significant difference in the overall survival was found between the groups stratified based on the GPS, NLR (p < 0.001). The GPS had a higher AUC value (0.905) in comparison to the NLR (0.648). In the multivariate analysis, the sex (p = 0.002), CA19-9 (p < 0.0001) and the GPS (p < 0.0001) were found to be independently associated with the overall survival. Our results demonstrate that the GPS is an independent marker of the prognosis in patients with BTC undergoing palliative chemotherapy or BSC, and is superior to the NLR in terms of its prognostic ability.

Entities:  

Mesh:

Year:  2013        PMID: 24310810     DOI: 10.1007/s12032-013-0787-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  34 in total

1.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

2.  Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.

Authors:  Eiichiro Suzuki; Junji Furuse; Masafumi Ikeda; Takuji Okusaka; Kohei Nakachi; Shuichi Mitsunaga; Hideki Ueno; Chigusa Morizane; Shunsuke Kondo; Satoshi Shimizu; Yasushi Kojima; Atsushi Hagihara
Journal:  Oncology       Date:  2010-11-10       Impact factor: 2.935

3.  Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

Authors:  D Gomez; S Farid; H Z Malik; A L Young; G J Toogood; J P A Lodge; K R Prasad
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

4.  Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.

Authors:  Wolfgang Sieghart; Matthias Pinter; Florian Hucke; Ivo Graziadei; Maximilian Schöniger-Hekele; Christian Müller; Wolfgang Vogel; Michael Trauner; Markus Peck-Radosavljevic
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

5.  Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma.

Authors:  Takashi Kobayashi; Masanori Teruya; Tomokazu Kishiki; Daisuke Endo; Yoshiharu Takenaka; Hozumi Tanaka; Kenji Miki; Kaoru Kobayashi; Koji Morita
Journal:  Surgery       Date:  2008-09-26       Impact factor: 3.982

6.  A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.

Authors:  Junji Furuse; Takuji Okusaka; Shinichi Ohkawa; Michitaka Nagase; Akihiro Funakoshi; Narikazu Boku; Kenji Yamao; Taketo Yamaguchi; Toshiya Sato
Journal:  Cancer Chemother Pharmacol       Date:  2009-04-29       Impact factor: 3.333

7.  Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer.

Authors:  D C McMillan; M M Elahi; N Sattar; W J Angerson; J Johnstone; C S McArdle
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

Review 8.  Classification, diagnosis, and management of cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Clin Gastroenterol Hepatol       Date:  2012-09-13       Impact factor: 11.382

Review 9.  Diagnosis and management of acute cholangitis.

Authors:  John G Lee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-04       Impact factor: 46.802

Review 10.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

View more
  11 in total

1.  Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.

Authors:  Toshikazu Moriwaki; Kazunori Ishige; Masahiro Araki; Shigemasa Yoshida; Masaaki Nishi; Mikio Sato; Takeshi Yamada; Yoshiyuki Yamamoto; Mitsuharu Ozeki; Hiroyasu Ishida; Takashi Yamaguchi; Kenji Matsuda; Tetsuya Murashita; Masato Abei; Ichinosuke Hyodo
Journal:  Med Oncol       Date:  2014-10-16       Impact factor: 3.064

Review 2.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

3.  The Glasgow Prognostic Score and stricture site can predict prognosis after endoscopic duodenal stent placement for malignant gastric outlet obstruction.

Authors:  Yu Takamatsu; Nao Fujimori; Tsukasa Miyagahara; Yuta Suehiro; Toyoma Kaku; Ken Kawabe; Akihisa Ohno; Kazuhide Matsumoto; Masatoshi Murakami; Katsuhito Teramatsu; Ayumu Takeno; Takamasa Oono; Yoshihiro Ogawa
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

Review 4.  Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis.

Authors:  Haowen Tang; Wenping Lu; Bingmin Li; Chonghui Li; Yinzhe Xu; Jiahong Dong
Journal:  Oncotarget       Date:  2017-05-30

5.  Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.

Authors:  Kyoung-Min Cho; Hyunkyung Park; Do-Youn Oh; Tae-Yong Kim; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang
Journal:  Oncotarget       Date:  2017-01-10

6.  Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer.

Authors:  Hyung Soon Park; Ji Soo Park; You Jin Chun; Yun Ho Roh; Jieun Moon; Hong Jae Chon; Hye Jin Choi; Joon Seong Park; Dong Ki Lee; Se-Joon Lee; Dong Sup Yoon; Hei-Cheul Jeung
Journal:  Cancer Res Treat       Date:  2017-02-06       Impact factor: 4.679

Review 7.  Biomarkers for Evaluating the Inflammation Status in Patients with Cancer.

Authors:  Ali Guner; Hyoung-Il Kim
Journal:  J Gastric Cancer       Date:  2019-09-09       Impact factor: 3.720

Review 8.  Inflammation based regulation of cancer cachexia.

Authors:  Jill K Onesti; Denis C Guttridge
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

Review 9.  Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis.

Authors:  De-Wen Tan; Yan Fu; Qi Su; Ming-Jun Guan; Po Kong; Sheng-Qiang Wang; He-Ling Wang
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

10.  The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma.

Authors:  Teruo Inamoto; Hideyasu Matsuyama; Shigeru Sakano; Naokazu Ibuki; Kiyoshi Takahara; Kazumasa Komura; Tomoaki Takai; Takuya Tsujino; Yuki Yoshikawa; Koichiro Minami; Kazuhiro Nagao; Ryo Inoue; Haruhito Azuma
Journal:  Oncotarget       Date:  2017-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.